Literature DB >> 21191607

Repeated percutaneous vertebroplasty for refracture of cemented vertebrae.

Lih-Huei Chen1, Ming-Kai Hsieh, Jen-Chung Liao, Po-Liang Lai, Chi-Chien Niu, Tsai-Sheng Fu, Tsung-Ting Tsai, Wen-Jer Chen.   

Abstract

BACKGROUND: Percutaneous vertebroplasty is an efficient procedure to treat painful osteoporotic vertebral compression fractures. However, refracture of cemented vertebrae occurs rarely after percutaneous vertebroplasty. This study was undertaken to investigate the incidence, characteristics, predisposing factors, and mistakes in technique associated with refracture of the same vertebra after percutaneous vertebroplasty.
METHODS: From 2001 to 2008, PVP with bone cement (polymethylmethacrylate, PMMA) was carried out in 2,291 patients with 2,581 PVP procedures. The etiologies including pathologic fracture (including metastasis, osteolytic tumor, hemangioma) in 299 patients, infectious spondylitis in 4 patients and osteoporotic compression fractures in 1,988 patients. A total of 1,988 patients with 2,110 VCFs underwent PVP with PMMA cement after failing conservative treatment for at least 3 months. New recollapsed vertebral fractures were diagnosed as recurrent intractable back pain, postoperatively correlated with serial plain radiography and MR image. Clinical parameters such as age, gender, body mass index, and fracture-free interval (from the date of the initial intervention with percutaneous vertebroplasty to the diagnosis of subsequent fractures) were recorded. Parameters related to imaging and technical characteristics, including the amount of bone cement injected per procedure, level, the presence of osteonecrosis in the vertebral body, and the surgical approach (uni- or bipedicles), the restoration of kyphosis angle and height of the anterior border of the collapsed vertebral body, and any leakage of cement into the disk space were also recorded.
RESULTS: In a 2-year follow-up, 1,800 patients with 1,820 VCFs were retrospectively reviewed and 10 patients with 10 VCFs developed refracture of the same vertebra after PVP with an incidence rate of 0.56% (10 in 1,800). The mean age of the ten patients (nine females and one male) was 79.6 years, and the mean BMI is 22.3. Levels of refracture after PVP were all located in the thoracolumbar junction (T12-L2): three in T12; four in L1; and three in L2. Osteonecrosis was present in all patients and intradiscal cement leakage was noted in five patients. The mean of the restoration of kyphosis angle was 7.7° and height of the anterior border was 26%. Osteonecrosis, greater anterior vertebral height restoration, lesser kyphosis angle correction and cystic filling pattern were statistically significant.
CONCLUSIONS: Our study suggests that larger height restoration and solid lump filling cement are risk factors of refracture of cemented vertebral bodies. Symmetric cement distribution and fluid aspiration would be the potential ways to avoid refracture of cemented vertebral bodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191607     DOI: 10.1007/s00402-010-1236-7

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  28 in total

1.  Diagnosis of painful cemented vertebrae from failed vertebroplasty: modified dynamic radiographs play an important role.

Authors:  Yen-Jen Chen; Hui-Yi Chen; Hsien-Te Chen; Ruey-Mo Lin; Horng-Chaung Hsu
Journal:  Eur Spine J       Date:  2017-03-31       Impact factor: 3.134

2.  Risk factor analysis for re-collapse of cemented vertebrae after percutaneous vertebroplasty (PVP) or percutaneous kyphoplasty (PKP).

Authors:  Yong-Xian Li; Dan-Qing Guo; Shun-Cong Zhang; Kai Yuan; Guo-Ye Mo; Da-Xing Li; Hui-Zhi Guo; Yongchao Tang; Pei-Jie Luo
Journal:  Int Orthop       Date:  2018-02-20       Impact factor: 3.075

3.  Optimizing bone cement stiffness for vertebroplasty through biomechanical effects analysis based on patient-specific three-dimensional finite element modeling.

Authors:  Yi Peng; Xianping Du; Lihua Huang; Jinsong Li; Ruisen Zhan; Weiguo Wang; Biaoxiang Xu; Song Wu; Cheng Peng; Shijie Chen
Journal:  Med Biol Eng Comput       Date:  2018-05-28       Impact factor: 2.602

4.  Biomechanical comparison of vertebral augmentation with silicone and PMMA cement and two filling grades.

Authors:  Tobias L Schulte; Alexander Keiler; Felix Riechelmann; Tobias Lange; Werner Schmoelz
Journal:  Eur Spine J       Date:  2013-07-24       Impact factor: 3.134

5.  Refracture of osteoporotic vertebral body concurrent with cement fragmentation at the previously treated vertebral level after balloon kyphoplasty: a case report.

Authors:  Xigong Li; Xianfeng Lou; Xiangjin Lin; Junhua Du
Journal:  Osteoporos Int       Date:  2014-02-20       Impact factor: 4.507

6.  Anterior spinal fixation for recollapse of cemented vertebrae after percutaneous vertebroplasty.

Authors:  Narihito Nagoshi; Kentaro Fukuda; Masanobu Shioda; Masafumi Machida
Journal:  BMJ Case Rep       Date:  2016-03-18

7.  The Use of SpineJack Intravertebral Implant for the Correction of Recurrent Vertebral Fracture After Kyphoplasty.

Authors:  Robert E Jacobson
Journal:  Cureus       Date:  2020-04-09

8.  Severe kyphotic deformity resulting from collapses of cemented and adjacent vertebrae following percutaneous vertebroplasty using calcium phosphate cement. A case report.

Authors:  Toshitaka Yoshii; Hiroko Ueki; Tsuyoshi Kato; Shoji Tomizawa; Atsushi Okawa
Journal:  Skeletal Radiol       Date:  2014-06-01       Impact factor: 2.199

9.  Cement bridging phenomenon in percutaneous vertebroplasty for adjacent vertebral compression fracture.

Authors:  Yun-Da Li; Tsung-Ting Tsai; Chi-Chien Niu; Po-Liang Lai
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

10.  Refracture of the cemented vertebrae after percutaneous vertebroplasty: risk factors and imaging findings.

Authors:  Yu-Chao Xiong; Wei Guo; Fan Xu; Ci-Ci Zhang; Zhi-Ping Liang; Li Wu; Song Chen; Xu-Wen Zeng
Journal:  BMC Musculoskelet Disord       Date:  2021-05-19       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.